Clinilabs Selected for a Phase I Study in Patients with Obstructive Sleep Apnea
Clinilabs
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Obstructive Sleep Apnea (OSA).
Clinilabs has been involved in clinical research related to the development of sleep therapeutics for 20 years. Barbara Smallwood, Vice President of Business Development, states “We are proud to continue our part in the search for new treatments for sleep disorders, and we look forward to assessing the effects of an investigational new drug on patients with OSA.”
Enrollment for this study is expected to begin in April 2011. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who have been diagnosed with OSA can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting
www.clinilabs.com/OSA
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
